Search research articles
Contact Us
Filters
Showing results (61-70 of 68) with videos related to
Page
of 7
Sort By:
You have reached the last page of results.
This site can display upto 68 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 25, 2015
Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort
J Mazières, F Barlesi, T Filleron, et al.
ESMO Open
|
November 11, 2025
Sex-specific efficacy and safety outcomes in patients with resectable stage III non-small-cell lung cancer (NSCLC) undergoing neoadjuvant therapies: a pooled analysis of the SAKK trials 16/96, 16/00, 16/01, 16/08 and 16/14
L Frehner, S Schär, S Hayoz, et al.
British Journal of Cancer
|
April 20, 2006
Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study
D C Betticher, S-F Hsu Schmitz, M Tötsch, et al.
ESMO Open
|
April 25, 2022
Corrigendum to 'Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials': [ESMO Open Volume 7, Issue 2, (2022), 100455]
D König, S Schär, D Vuong, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 16, 2019
Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial
S Peters, E Felip, U Dafni, et al.
ESMO Open
|
April 10, 2022
Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials
D König, S Schär, D Vuong, et al.
ESMO Open
|
July 13, 2023
Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14
D König, S Savic Prince, S Hayoz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 28, 2021
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial
R A Soo, J-Y Han, U Dafni, et al.
Page
of 7
Search research articles
Search
Showing results (61-70 of 68) with videos related to
Sort By:
Page
of 7
You have reached the last page of results.
This site can display upto 68 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 25, 2015
Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort
J Mazières, F Barlesi, T Filleron, et al.
ESMO Open
|
November 11, 2025
Sex-specific efficacy and safety outcomes in patients with resectable stage III non-small-cell lung cancer (NSCLC) undergoing neoadjuvant therapies: a pooled analysis of the SAKK trials 16/96, 16/00, 16/01, 16/08 and 16/14
L Frehner, S Schär, S Hayoz, et al.
British Journal of Cancer
|
April 20, 2006
Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study
D C Betticher, S-F Hsu Schmitz, M Tötsch, et al.
ESMO Open
|
April 25, 2022
Corrigendum to 'Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials': [ESMO Open Volume 7, Issue 2, (2022), 100455]
D König, S Schär, D Vuong, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 16, 2019
Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial
S Peters, E Felip, U Dafni, et al.
ESMO Open
|
April 10, 2022
Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials
D König, S Schär, D Vuong, et al.
ESMO Open
|
July 13, 2023
Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14
D König, S Savic Prince, S Hayoz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 28, 2021
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial
R A Soo, J-Y Han, U Dafni, et al.
Page
of 7